Polysaccharides Patents (Class 536/55.1)
-
Publication number: 20110136722Abstract: The present disclosure relates to a method for the sustained release of a drug, comprising the steps of: (a) preparing a biocompatible polymer having a hydrophobic group conjugated to the biocompatible polymer; and (b) contacting the biocompatible polymer to the drug for adsorbing the drug to the hydrophobic group of the biocompatible polymer, thereby obtaining a drug delivery carrier for the sustained release of the drug; wherein the drug is a protein, a peptide or a non-hydrophilic chemical drug; wherein when the drug adsorbed to the hydrophobic group of the biocompatible polymer is administered to a mammal, it shows a sustained release profile in the mammal. The drug delivery carrier according to the present disclosure having the hydrophobic group conjugated to the biocompatible polymer may be useful for adsorption of synthetic drugs having very low solubility in water.Type: ApplicationFiled: November 26, 2010Publication date: June 9, 2011Applicant: Pronexx Co., Ltd.Inventor: Soon-Chang Kwon
-
Patent number: 7956180Abstract: The present invention relates to products comprising hyaluronic acid or a salt thereof, which product is dried and agglomerated as defined herein, various compositions and articles comprising the product or compositions of the invention, methods of producing the product of the invention, and uses thereof.Type: GrantFiled: May 19, 2005Date of Patent: June 7, 2011Assignee: Novozymes A/SInventors: Poul Bach, Eric Thwaites
-
Patent number: 7943761Abstract: The present invention discloses a cellulose based optical film material with the following structure: wherein R1 is —H or —C(O)R4, R4 is alkyl or aryl; R2 is —C(O)R5, R5 is alkyl or aryl; R3 comprises one of the group consisting of: phosphinate based group, phosphonate based group, phosphonamide based group, phosphate based group, phosphoramide based group, carbamate based group, carbonate based group, and ester based group. Further, this invention also discloses a method for forming the cellulose based optical film material.Type: GrantFiled: October 19, 2006Date of Patent: May 17, 2011Assignee: National Taiwan Normal UniversityInventor: Chien-Tien Chen
-
Patent number: 7939655Abstract: A process for preparing a sterile ready-to-use aqueous pharmaceutical formulation comprises a high molecular weight hyaluronic acid salt (HA) at a specified concentration, comprising the steps of: providing an aqueous formulation comprising high molecular weight HA at a concentration of less than the specified final concentration; passing said aqueous formulation through a filter having a pore sizeless than 0.45 pm; concentrating said aqueous formulation by applying a vacuum and boiling off water until said specified concentration is reached.Type: GrantFiled: August 4, 2003Date of Patent: May 10, 2011Assignee: Laboratoire Medidom S.A.Inventor: Stefano Carlino
-
Patent number: 7928089Abstract: The present invention relates to mucoactive agents, such as heparin which are useful in the treatment of diseases where excess mucus is present in the respiratory tract, such as cystic fibrosis and chronic obstructive pulmonary disease. In particular, the invention relates to pharmaceutical compositions for administration by pulmonary inhalation. It also relates to methods for producing particles suitable for pulmonary inhalation, such as spray drying or jet milling.Type: GrantFiled: September 15, 2004Date of Patent: April 19, 2011Assignee: Vectura LimitedInventors: David Morton, David Ganderton, John Staniforth, Yorick Kamlag
-
Publication number: 20110070595Abstract: The present invention relates to immobilization compounds and methods useful for the identification of PARP interacting compounds or for the purification or identification of PARP proteins.Type: ApplicationFiled: May 14, 2009Publication date: March 24, 2011Inventors: Gerard Drewes, Valerie Reader
-
Publication number: 20110071274Abstract: The present invention refers to a method for binding a polycarboxylic acid to a solid phase. Further, the invention refers to a solid phase having a polycarboxylic acid immobilized thereto and methods of using the solid phase, e.g. for purifying His-tagged recombinant polypeptides.Type: ApplicationFiled: August 6, 2008Publication date: March 24, 2011Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.Inventors: Dirk Goerlich, Steffen Frey
-
Publication number: 20110065910Abstract: Carbohydrates having functional groups, such as carboxylic acid groups and methods of making such carbohydrates.Type: ApplicationFiled: November 19, 2010Publication date: March 17, 2011Applicant: XYLECO, INCInventor: Marshall Medoff
-
Publication number: 20110060139Abstract: A 1,2-dideoxy-1,2-diamino oligosaccharide or polysaccharide in its free base, salt or metal-complex form as shown in General Formula 1 and derivative thereof is described. R1, R2 and R3 are each independently selected from the group consisting of H and a carbohydrate moiety, with the proviso that at least one of the groups R1, R2 or R3 is a carbohydrate moiety; R4 is selected from the group consisting of: H, optionally substituted C1-20-alkyl, optionally substituted heteroalkyl, optionally substituted C2-20-alkenyl, optionally substituted C2-20-alkynyl, optionally substituted C3-10-cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.Type: ApplicationFiled: November 3, 2008Publication date: March 10, 2011Applicant: Glycom A/SInventors: Gyula Dekany, István Bajza, Marie Bøjstrup, Karoly Agoston, Lars Kröger, Figueroa Peréz, Christoph Röhrig, Paulo Vital, Erzsébet Czinege
-
Patent number: 7902170Abstract: The present invention is directed to human influenza virus binding substance containing at least one oligosaccharide chain, which comprises a terminal NeuNAc?6 linked to: (a) a linear or branched polylactosamine type structure consisting of at least three lactosamine residues, a linear sequence optionally containing one or two ?3-linked fucose residues in a non-sialylated lactosamine, a branched structure optionally carrying one or more additional NeuNAc?-residues at a terminal position in a branch, and/or (b) a linear or branched structure with two lactosamine and one lactose residue, a linear structure in addition containing one or two ?3-linked fucose residues in a non-sialylated lactosamine or lactose, a branched structure optionally carrying one additional NeuNAc?-residue in a terminal position of the branch, or an analog or derivative of said oligosaccharide chain for use in binding of human influenza virus.Type: GrantFiled: June 20, 2001Date of Patent: March 8, 2011Assignee: Biotie Theraples Corp.Inventors: Halina Miller-Podraza, Karl-Anders Karlsson
-
Publication number: 20110053887Abstract: A SOCS3 expression promoter includes hyaluronic acid having an average molecular weight of 500,000 or more and/or a salt thereof as an active ingredient.Type: ApplicationFiled: August 20, 2009Publication date: March 3, 2011Applicant: Q.P. CORPORATIONInventors: Tomoyuki Kanemitsu, Toshihide Sato, Akira Asari
-
Publication number: 20110024292Abstract: The present invention relates to derivatized cyclofructan compounds, compositions comprising derivatized cyclofructan compounds, and methods of using compositions comprising derivatized cyclofructan compounds for chromatographic separations of chemical species, including enantiomers. Said compositions may comprise a solid support and/or polymers comprising derivatized cyclofructan compounds.Type: ApplicationFiled: June 17, 2010Publication date: February 3, 2011Inventors: Daniel W. Armstrong, Ping Sun, Zachary S. Breitbach, Chunlei Wang
-
Patent number: 7875596Abstract: Dermatan sulfates and/or O-desulfated heparins useful in treating and preventing heparinoid-induced autoimmune responses, in particular heparin-induced thrombocytopenia (HIT) and its associated disease states. The dermatan sulfates comprise repeating disulfated and/or trisulfated disaccharide units of L-iduronic acid and N-acetyl-D-galactosamine. The O-desulfated heparins comprise heparin molecules selectively O-desulfated at the 2-O and/or 3-O positions of the uronic acid and glucosamine saccharide residues. Particularly effective dermatan sulfate HIT antagonists have a mean molecular weight of from about 2000 to about 10,000 Daltons.Type: GrantFiled: January 16, 2008Date of Patent: January 25, 2011Assignee: Celsus Biopharmaceuticals, Inc.Inventor: Alan D. Cardin
-
Patent number: 7868165Abstract: A process for the isolation of low-molecular weight aminoglycan compound of formula I made up of alternating glucuronic acid and N-acetyl glucosamine units; from a hitherto unexploited natural source of waste egg shells; which process comprises the steps of: wherein M may be at one or more instances Na, Ca, K, Mg: and n is an integer between 20 and 40: (a) pre-preparation of the waste egg-shells for extraction of the embryonic low molecular weight aminoglycan compound of formula I using a polar organic solvent in water; (b) extraction of the low molecular weight aminoglycan compound of formula I as its water soluble salt using an aqueous polar salt solution; (c) isolation of a purified low molecular weight aminoglycan compound of formula I by gel formation out of the aqueous salt mixture by using a polar organic solvent followed by filtration or centrifuging; (d) stabilization of the isolated aminoglycan extract by sequential introduction of organic oils into a semi-dried gel to form the aminoglycanType: GrantFiled: August 27, 2007Date of Patent: January 11, 2011Inventor: Bomi Patel-Framroze
-
Patent number: 7868166Abstract: A process is described for the continuous preparation and/or workup of polysaccharide derivatives by reaction and/or conditioning in a suspension with liquid reaction partners, in which, in accordance with FIG. 1, a) a preferably pumpable suspension stream of solids SE and liquid phase LE, if appropriate preheated to 185° C.Type: GrantFiled: May 2, 2003Date of Patent: January 11, 2011Inventors: Volker Eckhardt, Martin Lohrie, Bernd Schriewer, Holger Tanneberger
-
Publication number: 20100317617Abstract: A silver nanocomposite, a formation method for forming the silver nanocomposite, and an application method utilizing the silver nanocomposite. The silver nanocomposite includes a silver nanoparticle conjugated to a glycosaminoglycan (GAG) or glucose. The formation method includes chemically reacting silver nitrate with a reducing agent to form a silver nanoparticle conjugated to the reducing agent of a GAG or glucose. The application method may include topically applying the silver nanocomposite to a wound or burn as an anti-microbial with respect to an antibiotic-resistant genotype in the wound or burn, wherein the silver nanocomposite topically applied includes the silver nanoparticle conjugated to the GAG of 2,6-diaminopyridinyl heparin (DAPHP) or hyaluronan (HA). The application method may include applying the silver nanocomposite as a coating to plastic, a catheter, or a surgical tool, wherein the silver nanocomposite applied as the coating includes the silver nanoparticle conjugated to the GAG of DAPHP.Type: ApplicationFiled: June 9, 2010Publication date: December 16, 2010Applicant: VASCULAR VISION PHARMACEUTICAL CO.Inventors: Shaker A. Mousa, Robert Linhardt
-
Publication number: 20100311687Abstract: Non-crosslinked derivatives of oligo/polysaccharides of formula I, wherein: X is OH, OM, NH—R1, O—R1; M is an alkaline or alkaline-earth metal, transition metal, or cation containing a quaternary nitrogen atom; Y is H or R2; R1: the residue of an oligo/polysaccharide; R2: the residue of a C1-C4 linear chain aliphatic carboxylic acid or citric acid; provided that at least one X is NH—R1 or O—R1, while the other two X are present in acid (OH) or salified form (OM).Type: ApplicationFiled: December 18, 2007Publication date: December 9, 2010Inventors: Marco Bosco, Luca Stucchi, Fabrizio Picotti, Rita Gianni
-
Patent number: 7838510Abstract: The use in the medical-surgical field of biomaterials based on hyaluronic acid derivatives, optionally in association with natural, synthetic or semisynthetic biopolymers, for suppressing the angiogenic process associated with tumor proliferation (in primary and secondary tumors) is disclosed.Type: GrantFiled: January 7, 2003Date of Patent: November 23, 2010Assignees: Fidia Farmaceutici S.P.A., Deutsches KrebsforschungszentrumInventors: Norbert E. Fusenig, Hans-Jürgen Stark, Michael Willhauck, Alessandra Pavesio
-
Patent number: 7833766Abstract: Compositions of proteins having free thiols, and methods of making and using such compositions, are described.Type: GrantFiled: February 6, 2007Date of Patent: November 16, 2010Assignee: Shire Human Genetic Therapies, Inc.Inventors: Gaozhong Zhu, Vinh T. Nguyen, Kris Lowe, Zahra Shahrokh
-
Patent number: 7834173Abstract: The present invention relates to esters of hyaluronic acid with rhein, more particularly to a compound based on hyaluronic acid, wherein alcohol groups of hyaluronic acid are esterified with rhein, to a process for preparing said ester and to a pharmaceutical composition comprising said ester.Type: GrantFiled: February 25, 2005Date of Patent: November 16, 2010Assignee: Laboratoire Medidom S.A.Inventors: Antonello Pietrangelo, Valter Travagli
-
Patent number: 7825240Abstract: There are described novel cross-linked polymers based on bis-silane, bis-thioether, bis-sulphoxide, bis-sulphone and butane-di-yl derivatives of polysaccharides and oligosaccharides, their shaping as support materials useful for the separation or preparation of enantiomers; a process for preparing the said cross-linked polymer compounds, a process for preparing balls of support materials containing the said cross-linked polymer compounds; a method of obtaining balls of support materials useful in chromatography or in organic synthesis; and the use of the said support materials containing the cross-linked polymer compounds in separation or in preparation of enantiomers, through employment in chromatography or organic synthesis processes in a heterogeneous medium; and the use of the said cross-linked polymer compounds in the form of membranes in processes using percolation through membranes for the separation or the preparation of enantiomers.Type: GrantFiled: October 29, 2003Date of Patent: November 2, 2010Assignee: Eka Chemicals ABInventor: Raphaël Duval
-
Patent number: 7820638Abstract: A method for lubricating an implant or graft prior to implantation into a target implant site which enhances the lubricity of the implant or graft and promotes bone growth. The method comprises the steps of lubricating the implant or graft with the composition comprising hyaluronic acid and optionally a growth factor and/or an antiseptic and/or antibiotic, and subsequently implanting the lubricated implant or graft into a target implant site.Type: GrantFiled: August 7, 2003Date of Patent: October 26, 2010Assignee: Arthrex, Inc.Inventor: R. Donald Grafton
-
Patent number: 7812006Abstract: The invention relates to conjugates derived from the reductive amination of the pneumococcus serotype 5capsular polysaccharide. The conditions for reductive amination differ from conventional conditions in that they make it possible to avoid the appearance of an undesirable compound which harms the immunogenicity of the conjugates. In carbon NMR spectrum, this undesirable compound is characterized by a resonance signal between 13 and 14 ppm. The aminated polysaccharides used to produce the conjugates therefore have a carbon NMR spectrum lacking a resonance signal between 13 and 14 ppm. The invention offers two conditions for reductive amination. According to a first method, the reductive amination is carried out at a slightly acidic pH (4-6.5) for at the very most 4 hours. According to a second method, the polysaccharide is first of all reduced, then fragmented and, finally, subjected to a reductive amination per se, under conditions which may or may not be conventional.Type: GrantFiled: January 15, 2004Date of Patent: October 12, 2010Assignee: Aventis Pasteur S.A.Inventors: Noëlle Mistretta, Emilie Danve, Monique Moreau
-
Publication number: 20100255097Abstract: Disclosed are polysaccharides containing residues of glucosamine or galactosamine in the repetitive unit, characterised by the presence of esters on the hydroxyls or amides on the amine functions, with lipoic acid or with mixtures of lipoic acid and formic acid.Type: ApplicationFiled: December 11, 2008Publication date: October 7, 2010Applicant: SIGEA S.R.L.Inventors: Fabrizio Picotti, Marco Bosco, Luca Stucchi, Matteo Fabbian
-
Patent number: 7807656Abstract: The invention relates to novel applications of pharmaceutical compositions containing preferably long-chain hyaluronic acids which are cross-linked or not cross-linked, and conventional adjuvants and/or supporting materials.Type: GrantFiled: May 22, 2003Date of Patent: October 5, 2010Inventor: Johannes Reinmüller
-
Publication number: 20100210587Abstract: The present invention is provides a crosslinked hyaluronan powder excellent in swellability in water and a method for simply producing the same. A method for producing the swellable crosslinked hyaluronan powder is characterized by comprising mixing a crosslinking agent with a hyaluronan powder in a state dispersed in a liquid medium containing a monovalent alcohol having 1 to 4 carbon atoms and a solubility of the hyaluronan powder of less than 0.1 g/L to cause a crosslinking reaction. Also, the swellable crosslinked hyaluronan powder produced by the method has a swelling ratio in water of 500% or more.Type: ApplicationFiled: September 26, 2008Publication date: August 19, 2010Applicant: SHISEIDO COMPANY LTD.Inventor: Tetsunori Matsumoto
-
Patent number: 7776840Abstract: This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body.Type: GrantFiled: February 21, 2007Date of Patent: August 17, 2010Assignee: Cutanea Life Sciences, Inc.Inventors: Robert J. Bitterman, Kimberly A. Forbes-McKean
-
Publication number: 20100196510Abstract: Disclosed are compositions for the treatment of neuropathy and in particular peripheral neuropathy. The compounds include low molecular weight glycosaminoglycans. The peripheral neuropathy may be due to cancer treatment drugs.Type: ApplicationFiled: July 25, 2008Publication date: August 5, 2010Inventors: Ernst Wulfert, James Robert Murray
-
Patent number: 7767655Abstract: A complex, water soluble polysaccharide fraction having potent immunostimulatory activity isolated from Aloe vera. The polysaccharide fraction has an apparent molecular weight above 2 million daltons. Its major glycosyl components are glucose, galactose, mannose and arabinose. The invention further includes pharmaceutical compositions containing the instant polysaccharide fraction, optionally in combination with acceptable pharmaceutical carriers and/or excipients. These pharmaceutical compositions may be used to provide immunostimulation to an individual in need of such treatment by administering to such an individual an effective amount of the composition. The polysaccharide fraction is also useful as a component of dietary supplements and as a standardization component of commercial Aloe products.Type: GrantFiled: January 12, 2007Date of Patent: August 3, 2010Assignee: University of MississippiInventors: David Stanley Pasco, Nirmal Derek Pugh, Mahmoud Elsohly, Samir Ross
-
Publication number: 20100184965Abstract: The invention relates to a complex consisted of a polysaccharide and an HBP, said polysaccharide being consisted from glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative. The invention also relates to a pharmaceutical composition comprising a complex according to the invention and to the use of a polysaccharide consisted of glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative, for the preparation of a pharmaceutical formulation of stable HBPs.Type: ApplicationFiled: September 28, 2009Publication date: July 22, 2010Applicant: ADOCIAInventors: Olivier Soula, Remi Soula, Martin Gaudier, Gerard Soula
-
Publication number: 20100178346Abstract: The present invention relates to materials comprising hyaluronic acid for replacement or augmentation of the nucleus pulposus The materials have a Poisson's ratio of 0.40 to 0.80 based on that of the human nucleus pulposus.Type: ApplicationFiled: February 1, 2008Publication date: July 15, 2010Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Neil R. Malhotra, Weiliam Chen, Dawn M. Elliott
-
Publication number: 20100173865Abstract: Methods of making conjugates comprising an anti-cancer agent and hyaluronic acid, together with mixtures of reaction products comprising such conjugates and methods of using such conjugates in therapeutic and research applications are disclosed.Type: ApplicationFiled: October 26, 2009Publication date: July 8, 2010Inventors: Jim Klostergaard, David Farquhar, Sukhen C. Ghosh, Roger Price, Vikas Kundra, Ralph S. Friedman
-
Publication number: 20100173427Abstract: Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam.Type: ApplicationFiled: October 22, 2009Publication date: July 8, 2010Inventors: Johnny Jose Valdez, Byung Sook Moon, Ki Chung, Alejandro A. Orozco
-
Publication number: 20100167991Abstract: The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates to a pharmaceutical composition, wherein the active principle is chosen from the group consisting of proteins, glycoproteins, peptides and nonpeptide therapeutic molecules. The invention also relates to the use of the functionalized polysaccharides according to the invention in the preparation of pharmaceutical compositions as described above.Type: ApplicationFiled: October 6, 2009Publication date: July 1, 2010Applicant: ADOCIAInventors: Remi Soula, Olivier Soula, Gerard Soula, Richard Charvet
-
Publication number: 20100160467Abstract: Provided are an organic-inorganic hybrid scaffold with surface-immobilized nano-hydroxyapatite, and a method for the fabrication thereof. The scaffold is fabricated by reacting an acid group present on a surface of nano-hydroxyapatite with a primary amine present on a surface of a polymer support in the presence of EDC (1-ethyl-3-dimethylaminopropyl carbodiimide) to immobilize nano-hydroxyapatite onto the surface of the polymer support. The surface of nano-hydroxyapatite is previously grafted with poly(ethylene glycol methacrylate phosphate) (PolyEGMP) having phosphonic acid functionality or with a polymer having carboxylic acid functionality.Type: ApplicationFiled: December 10, 2009Publication date: June 24, 2010Applicant: KOREA INSTITUTE OF CERAMIC ENGINEERING & TECHNOLOGYInventors: Sang Cheon Lee, Jeong Ho Chang, Jin Hyung Lee, Kyung Ja Kim, Sung Eun Kim, Ho Chan Hwang, Ke-Won Kang, Seog-Jin Seo, Jin-Young Kim
-
Publication number: 20100158796Abstract: An amide of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of general formula (1).: wherein R?NR6R7, or alcoholic group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, OH, O—, alcoholic group of hyaluronic acid, amino group of deacylated hyaluronic acid; R1, R2, R3, R4?H, SO3—, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, —CO—(CH2)2—COOY; Y=negative charge, or H; R5?—CO—CH3, H, SO3—, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, acylic group of hyaluronic acid; R6=is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted; R7=is H or an aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted; wherein at least one of R or R5 forms an amide group.Type: ApplicationFiled: November 20, 2009Publication date: June 24, 2010Inventors: Davide BELLINI, Alessandra TOPAI
-
Patent number: 7741474Abstract: This invention relates to novel carbohydrate polymers with hydrophobic and hydrophilic side-groups suitable for solubilising, for example, hydrophobic drugs. The chain length of the carbohydrate polymeric backbone, and the type and number of the hydrophobic and hydrophilic side-groups are specifically chosen to improve the solubility properties of the carbohydrate polymers.Type: GrantFiled: September 22, 2003Date of Patent: June 22, 2010Assignee: The School of Pharmacy, University of LondonInventors: Ijeoma Uchegbu, Andreas Schatzlein, Ailsa Stewart, Clive Wilson
-
Publication number: 20100121034Abstract: The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs.Type: ApplicationFiled: January 15, 2010Publication date: May 13, 2010Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Patent number: 7713637Abstract: Provided herein are a coating or a device (e.g., absorbable stent) that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.Type: GrantFiled: March 3, 2006Date of Patent: May 11, 2010Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Lothar W. Kleiner, Connie S. Kwok
-
Publication number: 20100113385Abstract: The invention concerns a complex based on an organic silicon derivative. The invention is characterized in that said derivative is combined, by weak bonds, with one or several hyaluronic acid calibrated fragments of molecular weight comprised between 150 and 750 kDa, said derivative being of general formula (I): RXSi(OH)4-x??(I) wherein: R is a (C1-C4)alkyl, x=1 and 2. The invention also concerns the use of such a complex in the prevention or the repair of cutaneous damages.Type: ApplicationFiled: October 2, 2009Publication date: May 6, 2010Applicant: EXZYMOL S.A.M.Inventor: Marie-Christine Seguin
-
Patent number: 7700747Abstract: A process for producing a polysaccharide sponge comprises the steps of (A) freezing a photoreactive polysaccharide solution, and (B) irradiating the frozen photoreactive polysaccharide solution with light to crosslink the photoreactive polysaccharide, thereby obtaining the polysaccharide sponge. The process includes simplified steps requiring no removal of solvent, and has such an advantage that impurities are easily removed therefrom.Type: GrantFiled: October 29, 2007Date of Patent: April 20, 2010Assignee: Seikagaku CorporationInventor: Tomoya Sato
-
Publication number: 20100093659Abstract: The present invention is directed to conjugates for biorecognition comprising (i) an carbohydrate backbone structure (PO) of 5 to 20 monosaccharide units, (ii) oligosaccharide biorecognition groups (Bio) of 1 to 10 monomer units, (iii) a bifunctional spacer groups of the formula -(y)p-(S)q-(z)r-, wherein S is a spacer group, p, q and r are each 0 or 1, whereby at least one of p and r is different from 0, and y and z are chemoselective ligation groups, which covalently link a said Bio group to said backbone structure, and the degree of conjugation, indicating the average number of covalently attached Bio biorecognition groups per monomer unit of the backbone, being from 0.2 to 1. The invention is also directed to processes for their preparation, intermediates for use in the process as well as use of said conjugates, especially for inhibiting pathogenic bacteria.Type: ApplicationFiled: December 13, 2007Publication date: April 15, 2010Applicant: GLYKOS FINLAND OYInventors: Jari Natunen, Jari Helin, Krista Weikkolainen
-
Patent number: 7687478Abstract: An asparagine-linked disialoundecaoligosaccharide-fatty acid amide, a drug containing the same, and a drug containing an asparagine-linked disialoundecaoligosaccharide.Type: GrantFiled: June 29, 2004Date of Patent: March 30, 2010Assignee: Otsuka Chemical Co., Ltd.Inventors: Yasuhiro Kajihara, Hiroaki Maeda, Kazuhiro Fukae
-
Patent number: 7687249Abstract: The present invention relates to a process for the preparation of sulphated glycosaminoglycans derived from N— acetylheparosan which comprises: a) N-deacetylation and N-sulphation of the N-acetylheparosan polysaccharide prepared from natural or recombinant bacterial strain, preferably K5 E. coli, b) enzymatic epimerization with the glucuronyl C5-epimerase enzyme, c) partial O-sulphation followed by a partial O-desulphation, d) partial 6-O-sulphation, e) N-sulphation and an intermediate step of controlled depolimerization characterised by the fact that both O-sulphations (O-sulphation and 6O-sulphation) are partial. Furthermore the invention relates to the products obtained according to the process which show a ratio between the anti-Xa activity and anti-IIa activity equal to or higher than 1 and to compositions comprising said products in combination with suitable and pharmaceutically acceptable excipients and/or diluent.Type: GrantFiled: July 7, 2004Date of Patent: March 30, 2010Assignee: Inalco S.p.A.Inventors: Marco Manoni, Liana Salsini, Jacopo Chini, Giovanni Cipolletti
-
Patent number: 7674839Abstract: The invention relates to methods for the production of polymer carrier materials for solid phase synthesis, particularly for peptide synthesis. (Meth)acrylamide derivatives based on carbon hydrates, which can also contain other protective groups, are polymerized by means of suspension polymerization in an aqueous phase, optionally with the addition of pore-forming additives, and subsequently the protective groups are fully or partially cleaved. It is thus possible to obtain polymer carriers whose morphology (particle size, porosity), degree of cross-linking and swelling capability in aqueous and organic media can be adjusted in a targeted manner and whose reactive groups offer multiple opportunities for the immobilization of anchor groups and protective groups. The hydroxyl groups of the polymer carrier can be activated according to usual methods of solid phase synthesis.Type: GrantFiled: June 24, 2005Date of Patent: March 9, 2010Assignee: Technische UniversitatInventors: Thomas Verdianz, Heinrich Gruber, Simone Knaus, Alexander Poschalko
-
Publication number: 20100055184Abstract: The present invention provides hydrogels and compositions thereof for vocal cord repair or augmentation, as well as other soft tissue repair or augmentation (e.g., bladder neck augmentation, dermal fillers, breast implants, intervertebral disks, muscle-mass). The hydrogels or compositions thereof are injected into the superficial lamina propria or phonatory epithelium to restore the phonatory mucosa of the vocal cords, thereby restoring a patient's voice. In particular, it has been discovered that hydrogels with an elastic shear modulus of approximately 25 Pa are useful in restoring the pliability of the phonatory mucosa. The invention also provides methods of preparing and using the inventive hydrogels.Type: ApplicationFiled: September 3, 2009Publication date: March 4, 2010Inventors: Steven M. Zeitels, Robert Edward Hillman, Sandeep Sidram Karajanagi, Robert S. Langer
-
Publication number: 20100056488Abstract: The invention features corticosteroids conjugated to either a charged group or a bulky group in a manner that resists in vivo cleavage, the resulting conjugate is a peripherally acting steroid with reduced activity in the central nervous system. The invention provides a method for treating a patient having an inflammatory disease by administering to the patient a corticosteroid conjugate.Type: ApplicationFiled: November 4, 2009Publication date: March 4, 2010Applicant: The McLean Hospital CorporationInventors: Martin H. Teicher, Susan L. Andersen-Navalta
-
Patent number: 7662954Abstract: An outer layer having an entanglement comprising an intermingling of cloaked hydrophilic guest and a hydrophobic polymer host, wherein molecules of the guest have been crosslinked with each other. Under certain circumstances, using complexes of the guest may be desirable or even necessary. The intermingling of the guest and host includes a physical tangling, whether it also comprises crosslinking by primary bonding (e.g., chemical/covalent bonding) there-between. Also a method of producing an outer layer having such an entanglement, including the steps of: temporarily cloaking at least a portion of the hydrophilic groups of the guest; intermingling at least a portion of the cloaked groups with a porous polymeric structure by diffusing the guest with cloaked groups into at least a portion of the structure's pores; within the pores, crosslinking at least a portion of the molecules of the guest with the guest; and removing the cloaking. Cloaking may be performed by silylation or acylation.Type: GrantFiled: October 29, 2002Date of Patent: February 16, 2010Assignee: Colorado State University Research FoundationInventors: Susan P. James, Min Zhang, Guy Beauregard
-
Publication number: 20100028399Abstract: The present invention relates to the use of a thiol-group-containing polymer for preparing an implant for tissue augmentation, wherein the basis polymer is a polysaccharide.Type: ApplicationFiled: December 21, 2007Publication date: February 4, 2010Applicant: CROMA-PHARMA GESELLSCHAFT M.B.H.Inventor: Margit Hornof
-
Publication number: 20100028559Abstract: Devices comprising functionalized materials, and embodiments of a method for making and using such devices, are disclosed. Exemplary devices include ophthalmic devices, nanoparticles, quartz crystal microbalances, microarrays, and nanocomposites. In particular embodiments, device surfaces are modified with monomers and/or polymers, typically carbohydrate monomers and/or polymers. Embodiments of a method for making and using such devices are disclosed. Monomers and/or polymers are covalently bonded to surfaces using functionalized perhalophenylazides. In some embodiments, device surfaces are functionalized with a perhalophenylazide. One or more monomers and/or polymers subsequently are covalently bonded to the device surface using the perhalophenylazide. In other embodiments, monomers and/or polymers are derivatized with a functionalized perhalophenylazide. The derivatized monomers and/or polymers then are covalently bonded to the device surface using the perhalophenylazide.Type: ApplicationFiled: May 28, 2009Publication date: February 4, 2010Inventors: Mingdi Yan, Olof Ramström, Li-Hong Liu, Xin Wang, Michael M. Lerner, Tosapol Maluangnont